Methoxy-substituted benzoquinones

Other Names

1,4-benzoquinone, 2,6-dimethoxy-2,3-dimethoxy-1,4-benzoquinone2,5-cyclohexadiene-1,4-dione, 2,5-dimethoxy-2,5-cyclohexadiene-1,4-dione, 2,6-dimethoxy-2,5-cyclohexadiene-1,4-dione, 2-methoxy-2,5-dimethoxy-1,4-benzoquinone2,5-dimethoxy-p-benzoquinone2,5-dimethoxybenzo-1,4-quinone2,5-dimethoxybenzoquinone2,6-dimethoxy-1,4-benzoquinone2,6-dimethoxy-2,5-cyclohexadiene-1,4-dione2,6-dimethoxy-p-benzoquinone2,6-dimethoxy-p-benzosemiquinone2,6-dimethoxybenzo-1,4-quinone2,6-dimethoxybenzoquinone2,6-dimethoxycyclohexa-2,5-diene-1,4-dione2,6-dimethoxyquinone2,6-DMBQ2-MBQ2-methoxy-1,4-benzoquinone2-methoxy-p-benzoquinone2-methoxybenzo-1,4-quinone2-methoxybenzoquinone2-methoxycyclohexa-2,5-diene-1,4-dioneDBQDMBQDMOBQmethoxy-p-benzoquinonemethoxy-p-benzoquinonesmethoxy-substituted 1,4-benzoquinonesmethoxybenzoquinonesp-benzoquinone, methoxyp-xyloquinonexyloquinone

Synopsis

Methoxy-Substituted Benzoquinones

1. Identity, Chemical Classification, and Nomenclature

Methoxy-substituted benzoquinones are a class of naturally occurring organic compounds belonging to the broader family of 1,4-benzoquinones (para-benzoquinones). Quinones are cyclic organic compounds characterized by two carbonyl groups (C=O) incorporated within a conjugated ring structure. Within this class, the methoxy-substituted variants carry one or more methoxy (–OCH₃) groups attached to the ring, markedly altering their electron density, redox potential, and biological reactivity compared to unsubstituted benzoquinone.

The two principal members studied in the dietary supplement context are:

2-Methoxy-1,4-benzoquinone (2-MBQ; methoxybenzoquinone; MBQ) — a mono-methoxy derivative of 1,4-benzoquinone.
2,6-Dimethoxy-1,4-benzoquinone (DMBQ; 2,6-DMBQ; DBQ; dimethoxybenzoquinone) — the most extensively investigated form, carrying methoxy groups at the 2 and 6 positions. 2,6-Dimethoxybenzoquinone is an organic compound with the molecular formula C₈H₈O₄ and a molecular weight of 168.15 g/mol. It belongs to the class of benzoquinones, featuring a cyclohexadiene ring with two carbonyl groups at positions 1 and 4, and methoxy substituents at positions 2 and 6, resulting in a yellow solid with a melting point of 252 °C.

A third notable member, found primarily in certain Primula species, is primin (2-methoxy-6-pentyl-1,4-benzoquinone). Primin (2-methoxy-6-pentyl-1,4-benzoquinone) and its benzoquinone derivatives were detected in exudates from some European Primula species. Primin is principally of toxicological and allergological interest (see Safety section) rather than a target of supplemental use. The dietary supplement literature focuses almost exclusively on 2-MBQ and DMBQ as the active constituents of fermented wheat germ extract (FWGE), the most commercially prominent preparation standardized for these compounds.

Quinones are distributed widely in living organisms. Some of the more familiar ones are plastoquinone and phylloquinone, both quinones needed in photosynthesis, and ubiquinone, also known as coenzyme Q10, which participates in aerobic cellular respiration. All of the above are substituted p-benzoquinones. Methoxy-substituted benzoquinones thus occupy a biochemically significant niche within this large redox-active natural product family.

2. Natural Sources and Distribution

Methoxy-substituted benzoquinones occur across a wide range of plants, fungi, and fermented foods. Their presence and bioavailability, however, differ substantially depending on the source and on whether they exist in free (aglycone) or glycosylated form.

2.1 Wheat Germ (Primary Supplement Source)

While native wheat germ contains physiologically inactive glycosylated quinones, fermentation, particularly via yeast glycosidases, releases bioactive quinones, such as benzoquinone, 2-methoxy benzoquinone, and 2,6-dimethoxy benzoquinone, which are present in FWGE. The parent plant is wheat (Triticum vulgare / Triticum aestivum), and the biologically active forms are liberated only through enzymatic hydrolysis of the glycoside bond during fermentation. 2-Methoxy benzoquinone and 2,6-dimethoxybenzoquinone are naturally present in wheat germ as a glycosylated and non-physiologically active form.

2.2 Grapes and Red Wine

DMBQ has been identified in Vitis coignetiae (yamabudo, the Asian wild grape) and in red wines derived from Vitis vinifera. Three components comprising 2,6-dimethoxy-1,4-benzoquinone (DBQ), fertaric acid and caftaric acid were isolated and identified from the juice of V. coignetiae as anti-inflammatory ingredients. In regard to the beverage context, DMBQ is probably formed in plants via oxidative degradation of the anthocyanin malvidin and its glycosides; whereas no DMBQ was detected in white wines, concentrations between 28 and 137 μg/l were measured in red wines. In vivo formation kinetics in crushed anthocyanin-rich fruits were monitored, and up to 2.84 mg/kg DMBQ were found, showing that its formation was triggered by cell disruption and catalysed by intrinsic oxidases.

2.3 Other Plant Sources

2,6-Dimethoxy-1,4-benzoquinone is a natural product found in Iris milesii, Diospyros eriantha, and other organisms. 2,6-Dimethoxybenzoquinone (2,6-DMBQ) has also been found in Rauvolfia vomitoria and in Tibouchina pulchra. DMBQ is one of the components isolated from the rhizome of Gynura japonica with potential anti-platelet aggregation activity in vitro. Additionally, it is formed as a product due to the activity of bacterial Azospirillum lipoferum laccase on phenolic compounds of the syringic type.

2.4 Primin in Primula Species

Miconidin (2-methoxy-6-pentyl-1,4-dihydroxybenzene) and the allergen primin (2-methoxy-6-pentyl-1,4-benzoquinone) have been isolated from fresh plant material (leaves, stems and flowers together) of Primula obconica. Primin is responsible for the notorious contact dermatitis caused by ornamental primroses and is not used as a dietary supplement.

3. Common Forms, Preparations, and Regulatory Status

In the dietary supplement market, methoxy-substituted benzoquinones are not typically sold as isolated pure compounds. They are instead delivered via standardized extracts of fermented wheat germ, in which their concentration serves as a quality control marker.

Fermented Wheat Germ Extract (FWGE) — Avemar®: FWGE is derived from wheat germ, a by-product of wheat processing, through fermentation with Saccharomyces cerevisiae. The most widely studied and patented form of FWGE is marketed as Avemar (also referred to as MSC), standardized to contain methoxy-substituted benzoquinones. FWGE, standardized for methoxy-substituted benzoquinones, was registered in Hungary as a medical food in 2002. This patented product contains 2,6-dimethoxy-1,4-benzoquinone (DMBQ) and 2-methoxy-benzoquinone at concentrations of approximately 400 μg/g (0.04%) of the crude extract.
Standardization level: The composition of FWGE is standardized to a 2,6-dimethoxy-p-benzoquinone content of 0.4 mg/g on a dry matter basis.
Regulatory standing: Fermented wheat germ extract (FWGE) is one of the few fermented food products listed in the EFSA novel food catalogue. The FWGE nutraceutical (Avemar), manufactured under "good manufacturing practice" conditions and fulfilling the self-affirmed "generally recognized as safe" status in the United States, has been approved as a "dietary food for special medical purposes for cancer patients" in Europe. In the United States, FWGE is marketed as a dietary supplement, Avé®, by American BioSciences, Inc. FWGE is manufactured as Avemar® in Hungary, where it is approved as a "medical nutriment" for cancer patients.
Physical presentation: FWGE/Avemar is commercially available primarily as a powder (Avemar pulvis) intended to be dissolved in water, as well as in granule form, for oral consumption.
Lactic acid bacteria fermentation route: Beyond yeast-based fermentation, research has demonstrated an alternative production route. Lactobacillus plantarum LB1 and Lactobacillus rossiae LB5 were selected based on the highest enzyme activity and technology features and used in combination to ferment wheat germ. During incubation, the release of the non-glycosylated and physiologically active 2-methoxy benzoquinone, and 2,6-dimethoxybenzoquinone was almost completed during 24 h, with concentration of the above bioactive compounds increasing almost 4- and 6-folds compared to the control.

4. Traditional and Historical Use

Methoxy-substituted benzoquinones as isolated, identified chemical entities have no independent tradition of use. Their documented history begins in the mid-twentieth century with chemical synthesis and natural product isolation, and the modern era of their supplemental use originated in Hungary in the early 1990s.

Fermented wheat germ extract (FWGE, Avemar pulvis) was invented by Hungarian biochemist Máté Hidvégi in the early 1990s. Hidvégi's work built on earlier findings relating fermented plant products to immune stimulation, and on the concept, originally attributed to the Hungarian Nobel laureate Albert Szent-Györgyi, that quinones derived from wheat germ might interfere with cellular energy metabolism in tumor cells.

Wheat germ itself has a much longer history as a nutritional ingredient, used broadly in European and North American food traditions as a concentrated source of vitamins, minerals, and protein. However, the targeted use of fermented wheat germ as a source of standardized benzoquinones for clinical purposes is an entirely modern development, with no traditional ethnobotanical or pre-modern medical record. Since the early 1990s, international attention has accelerated in the investigation and use of a fermented wheat germ extract called Avemar.

The use of wild grape (Vitis coignetiae, yamabudo) juice in Japan, from which DMBQ has since been isolated, does have a longer culinary tradition. Vitis coignetiae has been grown for the last two centuries; these species are used for wine, jam, and juice production in Japan. However, the attribution of specific health benefits to its benzoquinone content is a modern scientific rather than traditional observation.

5. Key Constituents and Active Compounds

The composition of FWGE includes two quinones, 2-methoxy benzoquinone and 2,6-dimethoxy benzoquinone (DMBQ), present in wheat germ as glucosides and standardized to a 2,6-dimethoxy-p-benzoquinone content of 0.4 mg/g on a dry matter basis. These quinones are believed to be largely responsible for the anticancer activity of FWGE. Although benzoquinones, peptides and phenolics are biologically active compounds in FWGE, a detailed characterization of the exact composition of the patented product is lacking.

Fermentation increases the levels of peptides and free phenolics while decreasing bound phenolics by altering protein-polyphenol interactions, and such changes may contribute to the biological activity of FWGE. The content of released benzoquinones in FWGE is influenced by the fermentation conditions.

FWGE is a multisubstance composition and, besides others, contains 2-methoxy benzoquinone and 2,6-dimethoxy benzoquinone, which are likely to exert some of its biological effects. FWGE interferes with anaerobic glycolysis, pentose cycle and ribonucleotide reductase.

6. Established Mechanisms of Action

Research has characterized several molecular mechanisms through which methoxy-substituted benzoquinones, particularly DMBQ, exert their biological effects. These mechanisms operate at the level of cellular metabolism, cell signaling, and immunomodulation.

6.1 Inhibition of Anaerobic Glycolysis

2,6-DMBQ inhibits anaerobic glycolysis, thereby preventing cellular metabolism and inducing apoptosis. This mechanism is of particular relevance to oncology because cancer cells characteristically rely on aerobic glycolysis (the Warburg effect) and anaerobic glycolytic pathways to fuel rapid proliferation. Among its proposed mechanisms, FWGE may suppress cancer cell proliferation by disrupting the glucose-related metabolic pathways.

6.2 Inhibition of Ribonucleotide Reductase and the Pentose Cycle

FWGE interferes with anaerobic glycolysis, the pentose cycle, and ribonucleotide reductase. It has significant antiproliferative effects and kills tumor cells by the induction of apoptosis via the caspase-poly [ADP-ribose] polymerase-pathway. Ribonucleotide reductase catalyzes the rate-limiting step in the biosynthesis of deoxyribonucleotides, which are essential building blocks for DNA replication; its inhibition starves rapidly dividing cells of the precursors needed for proliferation.

6.3 mTOR Inhibition

2,6-DMBQ significantly reduced cell growth and induced G1 phase cell cycle arrest and apoptosis in gastric cancer cells. 2,6-DMBQ reduced the activity of mTOR in vitro. The inhibition of cell growth by 2,6-DMBQ is dependent upon the expression of the mTOR protein. The mTOR (mammalian target of rapamycin) kinase is a master regulator of cell growth, protein synthesis, and metabolism; its inhibition is a well-established anticancer strategy.

6.4 Redox Activity and Prooxidant Effects in Tumor Cells

The mechanism of action for 2,6-dimethoxy-1,4-benzoquinone often involves its role as an electron acceptor in redox reactions. In biological systems, it may participate in electron transport processes or act as a signaling molecule due to its ability to undergo reversible redox transformations. It is an anticancer agent whose kinetics of cyclic redox transformation induced by ascorbate has been studied using the Clark electrode and ESR techniques. FWGE efficiently decreased cellular ROS production and lipid peroxidation in the case of LPS-induced inflammatory response; however, without LPS treatment, higher concentrations of FWGE increased the rate of both ROS and malondialdehyde synthesis. This observation may refer to the prooxidant activity of high-dose FWGE, which is an important beneficial effect regarding tumor cells.

6.5 Immunomodulation

FWGE modulates immune response by downregulation of MHC-I complex and the induction of TNF-α and various interleukins. FWGE stimulates the immune response against tumor cells by decreasing the MHC-I expression in the cell membrane and rendering cancer cells more effectively recognized by natural killer (NK) cells. In addition, 2,6-DMBQ exerts immune-enhancing effects by increasing natural killer (NK) cell and T-cell activity against cancer cells.

6.6 Anti-Inflammatory Signaling

A citric acid–treated wheat germ extract (which releases DMBQ) inhibited secretion of the pro-inflammatory cytokines tumor necrosis factor-α, interleukin (IL)-6, and IL-12 and the synthesis of cyclooxygenase-2, while both treated and untreated extracts induced high levels of anti-inflammatory IL-10 and heme oxygenase-1. The treated extract specifically inhibited phosphorylation of NF-κB p65 and p38 kinase at 15 min after LPS stimulation.

6.7 AKT/mTOR Signaling and Mitochondrial Function in Muscle

2,6-Dimethoxy-1,4-benzoquinone (DMBQ), a natural phytochemical present in fermented wheat germ, has been reported to exert anti-cancer, anti-inflammatory, and anti-adipogenic effects. Distinct from its cancer-related mechanisms, DMBQ also activates anabolic pathways in skeletal muscle, with evidence pointing to stimulation of the AKT/mTOR axis to promote protein synthesis and muscle hypertrophy.

6.8 Anti-Adipogenic Effects via AMPK

In 3T3-L1 adipocytes, 2,6-dimethoxy-1,4-benzoquinone (5–7.5 μM) suppresses adipogenesis via AMPK activation (phosphorylation increases 2.3-fold, inhibiting ACC and FAS), PPARγ downregulation (expression decreases by 58%, reducing lipid accumulation), and inflammatory cytokine modulation (TNF-α and IL-6 secretion drop by 40–45%). These effects position it as a potential anti-obesity agent, though in vivo validation remains pending.

6.9 Antimicrobial Activity

At physiological concentrations, 2,6-dimethoxybenzoquinone is an antibacterial substance. Investigations of the antibacterial activities of the 1,4-benzoquinone standards showed that DMBQ and benzoquinone were the most highly inhibitory to S. aureus and S. typhimurium, followed by MBQ and hydroquinone. MICs for DMBQ and benzoquinone ranged between 8 and 64 μg/ml against the four foodborne pathogens tested.

7. Scientific Evidence by Area of Use

7.1 Oncology: Cancer Adjunct Therapy

This is the most extensively researched application area for methoxy-substituted benzoquinones (delivered as FWGE). Evidence exists across in vitro, animal, and human clinical study levels, but the quantity and quality of clinical trials remain limited.

7.1.1 In Vitro Evidence

Both raw wheat germ (control) and sourdough fermented wheat germ were ex vivo assayed for anti-proliferative activity towards various cell lines of germ cell tumor, colon carcinoma, and ovarian carcinoma. While no effect was found for the raw wheat germ, the sourdough fermented preparation markedly and variously affected the human tumor cell lines, with IC₅₀ values ranging from 0.105 ± 0.005 to 0.556 ± 0.071 mg/ml.

FWGE exerts significant antitumor activity in a broad tumor model. Simultaneous drug exposure with FWGE and 5-FU, oxaliplatin, or irinotecan yielded additive to synergistic drug interaction. However, sequential drug exposure of 5-FU and FWGE in colon cancer cell lines appeared to be schedule-dependent, with 5-FU needing to precede FWGE.

Investigation of Avemar (FWGE) against a range of ovarian cancer (OVCA) cell lines, both alone and in combination with cisplatin chemotherapy, showed that FWGE exhibited significant antiproliferative effects against 12 human OVCA cell lines and potentiated cisplatin-induced apoptosis. Pearson correlation of FWGE sensitivity and gene expression data identified 2,142 genes representing 27 biologic pathways significantly associated with FWGE sensitivity.

In hepatocellular carcinoma cells, FWGE exhibited potential to suppress HepG2, Hep3B, and HepJ5 cells, with IC₅₀ values of 0.494, 0.371, and 1.524 mg/mL, respectively. FWGE induced PARP-associated cell death in Hep3B cells. Moreover, FWGE treatment further enhanced the cytotoxicity of cisplatin in all tested HCC cells, and cytotoxicity of 5-FU in a synergistic manner in HepJ5 cells.

In vitro evidence is consistently positive across numerous cell lines and cancer types. Evidence strength at this level is moderately strong but cannot be directly extrapolated to clinical outcomes.

7.1.2 Human Clinical Evidence — Melanoma

In a randomized, pilot, phase II clinical trial, the efficacy of dacarbazine (DTIC)-based adjuvant chemotherapy on survival parameters of high-risk skin melanoma patients was compared to that of the same treatment supplemented with a 1-year long administration of FWGE. Mean progression-free survival (PFS) was 55.8 months in the FWGE group versus 29.9 months in the control group (p = 0.0137). Mean overall survival (OS) was 66.2 months in the FWGE group versus 44.7 months in the control group (p = 0.0298). This is one of the most robustly designed individual trials in the FWGE literature; however, it was a pilot trial with limited sample size.

7.1.3 Human Clinical Evidence — Colorectal Cancer

Survival analysis in a colorectal cancer study showed significant improvements in the fermented wheat germ extract group regarding progression-free (p = 0.0184) and overall survival probabilities (p = 0.0278). Strong predictors of survival determined by Cox's proportional hazards were UICC stage and fermented wheat germ extract treatment. Mild gastrointestinal side effects were observed in 9 cases. Supportive application of fermented wheat germ extract in colorectal cancer was highly recommended by the authors. In one study of 170 colorectal cancer patients, not only were there no adverse effects due to adjunct therapy with Avemar pulvis, but also the survival rate was improved over those receiving standard therapy alone.

7.1.4 Overall Systematic Review Assessment

Out of 51 records identified by a systematic literature search of human studies conducted through PubMed, Scopus, and Cochrane Library, six studies met the inclusion criteria, and data from these studies were extracted and synthesized in summary tables.

Although six controlled trials consistently reported positive results, the evidence for the claimed benefits is very weak, due to high risk of bias in trials published. No placebo-controlled trials have been carried out.

These studies suggest there may be a role for Avemar in decreasing the progression of the disease, potentiating conventional treatments such as chemotherapy and radiotherapy, improving quality of life for sufferers, and potentially ameliorating or lessening side effects of conventional treatment. While the early evidence, particularly at the cellular level, is promising and of interest, the broader questions regarding Avemar as an adjunctive therapy in cancer treatment, and its clinical effectiveness, have not been established to date.

Evidence strength assessment (oncology): Preclinical (in vitro and animal) evidence is substantial and mechanistically coherent. Human clinical evidence is preliminary — based on a small number of trials, generally with modest sample sizes, high risk of bias, and absence of placebo controls in most studies. Results are consistently directionally positive but cannot be considered definitive.

7.2 Skeletal Muscle Hypertrophy and Physical Performance

The effect of DMBQ on muscle hypertrophy and myoblast differentiation has been investigated. To examine myogenic differentiation and hypertrophy, confluent C2C12 cells were incubated in differentiation medium with or without various concentrations of DMBQ for 4 days. In animal experiments, C57BL/6 mice were fed a DMBQ-containing AIN-93 diet for 7 weeks. Grip strength, treadmill, microscopic evaluation of muscle tissue, western blotting, and quantitative real-time PCR were performed. DMBQ significantly increased fusion index, myotube size, and the protein expression of myosin heavy chain (MHC).

Evidence strength assessment (muscle): Currently limited to in vitro cell culture and rodent studies. No human clinical trials have been conducted. Evidence is preliminary and cannot be extrapolated to clinical recommendations.

7.3 Anti-Inflammatory and Autoimmune Conditions

7.3.1 Rheumatoid Arthritis

Fifteen female rheumatoid arthritis (RA; Steinbrocker II-III) patients, who had unsuccessfully tried two different DMARD treatments, were enrolled in an open-label, 1-year long, pilot clinical study. DMARD and steroid therapies were recorded and continued. All patients received Avemar as additional therapy. For measurement of efficacy, the Ritchie Index, the Health Assessment Questionnaire (HAQ), and the assessment of morning stiffness were applied. Patients were evaluated at baseline, 6, and 12 months. The study authors concluded that supplementation of standard therapies with a continuous administration of Avemar is beneficial for RA patients.

Evidence strength assessment (RA): A single open-label pilot study with 15 participants. No control group, no blinding. Results are hypothesis-generating only and carry high risk of bias.

7.3.2 Systemic Lupus Erythematosus (SLE)

Scientific evidence suggests that FWGE may have anticancer effects. FWGE may also improve immune function-associated conditions such as rheumatoid arthritis and systemic lupus erythematosus. However, controlled clinical data for SLE remain very limited, and no independently replicated randomized trial has been published.

Evidence strength assessment (autoimmune): Weak overall; mechanistic plausibility exists given FWGE's documented immunomodulatory effects, but clinical evidence is insufficient to draw conclusions.

7.4 Antimicrobial Activity

While screening for antibacterial agents, researchers discovered that wheat germ extract contains 2,6-dimethoxy-1,4-benzoquinone (DMBQ) and is highly inhibitory to S. aureus and B. cereus. This was reported as the first report of the antibacterial activity of wheat germ extract. The naturally occurring 2,6-dimethoxybenzoquinone (DMBQ) has anti-bacterial, anti-fungal and anti-cancer activities.

Evidence strength assessment (antimicrobial): Demonstrated at MIC level in laboratory microbiological studies. No clinical data exist. Evidence is preclinical only.

7.5 Cancer Chemoprevention (Skin Tumorigenesis)

The anti-tumorigenic effect of DBQ on the promotion and initiation stages of mouse skin tumorigenesis was investigated, and topical administration of DBQ on the promotion stage significantly decreased tumor development in mice skin. DBQ is a potential candidate for the chemopreventive effect of V. coignetiae. Inhibitory effects were found of DBQ on the mutagenicity of dimethylbenzo[a]anthracene, aflatoxin B1, 3-amino-1-methyl-5H-pyrido[4,3-b]indole (Trp-P-2), and amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in the Ames test.

Evidence strength assessment (chemoprevention): Animal and in vitro antimutagenesis data only. No human chemoprevention trials have been conducted.

7.6 Anti-Adipogenic / Metabolic Effects

Preclinical in vitro data in adipocyte models are described above (Section 6.8). These effects position DMBQ as a potential anti-obesity agent, though in vivo validation remains pending. No human data exist for this indication.

7.7 Antioxidant / Hepatoprotective Effects

In noninflamed hepatocytes, considering the results of glutathione peroxidase activity, the application of FWGE did not result in severe oxidative distress. FWGE as a redox modulator, applied in the appropriate concentration, can serve as a promising candidate in the supplementary therapy of patients suffering from various inflammatory diseases, decreasing free radical generation and thus avoiding the occurrence of cytotoxic effects.

Evidence strength assessment (antioxidant/hepatoprotective): In vitro and animal data only. No human trials conducted specifically for this indication.

8. Body Systems Associated with Methoxy-Substituted Benzoquinones

Oncological system: Primary documented area of clinical interest; evidence for adjunctive use in multiple cancer types (melanoma, colorectal, ovarian, hepatocellular, gastric).
Immune system: Immunomodulatory actions including NK cell activation, MHC-I downregulation on tumor cells, and cytokine modulation (TNF-α, interleukins).
Musculoskeletal system: Preliminary evidence for promoting skeletal muscle differentiation and hypertrophy via AKT/mTOR signaling.
Metabolic / Adipose system: Anti-adipogenic effects demonstrated in cell culture via AMPK activation and PPARγ suppression.
Inflammatory signaling: Documented suppression of NF-κB, COX-2, and multiple pro-inflammatory cytokines.
Microbiology / Infection: Demonstrated antimicrobial properties against gram-positive and gram-negative foodborne pathogens in laboratory studies.

9. Dosage Forms and Dosages Reported in Studies

Dosage information available in the scientific literature relates exclusively to FWGE as the delivering preparation, not to isolated DMBQ or 2-MBQ.

Standard adult cancer adjunct dose (clinical studies): Adults diagnosed with various cancers were administered 8.5 g of Avemar pulvis daily in combination with chemotherapy or other drug therapies for periods averaging 7.9 to 32.2 months.
Colorectal cancer cohort study: An open-label cohort trial compared anticancer treatments plus MSC (9 g once daily) vs anticancer treatments alone in colorectal patients.
Rheumatoid arthritis study: In a study by Balint et al. (2006), 15 female rheumatoid arthritis patients were given twice-daily doses of 8.5 g Avemar pulvis/day, totaling 17 g/day, for a period of 12 months as a supplement to their steroid therapy.
Duration of safe use observed: A specific wheat germ extract (Avemar) has been used safely for about 29 months.
Standardized DMBQ content per dose: At the standard product concentration of 0.4 mg DMBQ per gram of extract, an 8.5 g daily dose delivers approximately 3.4 mg of 2,6-DMBQ per day, based on the standardization parameters reported in the literature.

10. Safety Considerations and Interactions

10.1 Acute and Subacute Toxicology

Acute and subacute toxicity studies using rodents orally administered Avemar pulvis showed that dose levels (2000 to 3000 mg/kg body weight/day) exceeding the normal recommended oral dosage (8.5 g/day or 121 mg/kg bw/day for a 70-kg individual) by up to approximately 25-fold caused no adverse effects. The test substance showed no evidence of mutagenicity or genotoxicity in vitro or in vivo.

Clinical studies using Avemar pulvis as a supplement to drug therapy in cancer patients at doses of 8.5 g/day not only showed no evidence of toxicity, but also showed a reduction in the side effects of chemotherapy. Overall, it was concluded that Avemar pulvis would not be expected to cause adverse effects under the conditions of its intended use as an ingredient in dietary supplements.

10.2 Mild Adverse Effects Reported

Mild gastrointestinal side effects were observed in 9 cases in the colorectal cancer survival study. In several of the cancer studies, Avemar pulvis supplementation appeared to reduce side effects (e.g., fatigue, constipation, nausea, fever or infection, and insomnia) compared to chemotherapy alone.

10.3 Primin — Contact Allergy Risk (Not Applicable to Dietary Supplement Use)

DMBQ (2,6-dimethoxy-1,4-benzoquinone) is a wood allergen, reported to cause various skin and mucosal symptoms on exposure to wood dusts. Separately, primin (2-methoxy-6-pentyl-1,4-benzoquinone) from Primula species is a well-documented cause of contact dermatitis. Miconidin and the allergen primin have been isolated from fresh plant material of Primula obconica, and the possibility that miconidin is an allergen in P. obconica is discussed. These dermatological concerns pertain to occupational and horticultural exposure, not to oral ingestion of FWGE supplements.

10.4 Contraindications

Organ transplant recipients: Hypothesized contraindications based on mechanistic studies (in vivo and in vitro) include hormone-sensitive cancers and transplant patients. Fermented wheat germ extract might increase the immune system, which might increase the risk of organ transplant rejection.
Gastrointestinal conditions: The manufacturer of the commercial formula advises against its use in cases of bleeding erosions or ulcers of the gastrointestinal tract, malabsorption syndrome, and gluten sensitivity (coeliac disease).
Pregnancy and breastfeeding: Due to a lack of data, use during pregnancy and breastfeeding should be avoided.
Hormone-sensitive cancers: Hypothesized contraindications based on mechanistic studies include hormone-sensitive cancers; however, data from oestrogen receptor-positive breast cancer cells showed increased tamoxifen activity when co-administered with FWGE.

10.5 Drug Interactions

Immunosuppressants: Fermented wheat germ extract seems to increase the immune system and may decrease the effectiveness of medications that decrease the immune system. Some medications that decrease immune system activity include azathioprine (Imuran), basiliximab (Simulect), cyclosporine (Neoral, Sandimmune), daclizumab (Zenapax), muromonab-CD3, mycophenolate (CellCept), tacrolimus (FK506, Prograf), sirolimus (Rapamune), prednisone, corticosteroids, and others.
Vitamin C: Do not take FWGE within 2 hours of taking Vitamin C or multivitamins. High doses of Vitamin C can neutralize the active benzoquinones in the extract. This is consistent with the known chemistry of ascorbate as a reductant of quinone structures.
Heat stability: Never mix the extract with hot water or tea, as heat destroys the active biological components.

10.6 Pediatric Population

The available evidence regarding the safety of FWGE in children is currently limited to a single clinical study (Garami 2004). This represents a significant knowledge gap.

10.7 Gluten Sensitivity

Because FWGE originates from wheat germ, it may pose a risk for individuals with coeliac disease or wheat sensitivity. The manufacturer's own contraindications include gluten sensitivity, though the extent to which the fermentation process affects residual gluten content has not been definitively addressed in the reviewed literature.

11. Summary of Evidence Quality

The body of research on methoxy-substituted benzoquinones — particularly DMBQ delivered via FWGE (Avemar) — reflects a compound that has been the subject of genuine scientific investigation across multiple cancer types and inflammatory conditions. FWGE (Avemar) is a dietary supplement with reported potential for cancer prevention and therapy. Studies have demonstrated that wheat germ extract fermented with Saccharomyces cerevisiae possesses antioxidant, anti-inflammatory, and anticarcinogenic effects in a range of human cancer cell lines, including testicular, colon, melanoma, and leukemia cells. However, available data so far justify the use of FWGE as a non-prescription medical nutriment for cancer patients, and further randomized, controlled and large-scale clinical studies are mandatory to further clarify the value of FWGE as a drug component of future chemotherapy regimens.

The overall evidentiary picture is as follows: mechanistic and in vitro data are extensive and coherent; animal data are supportive; human clinical data are positive in direction but limited in number, scale, and methodological rigor. Large-scale, double-blind, placebo-controlled trials are absent. The weight of evidence justifies continued clinical investigation but does not yet support definitive efficacy claims for any indication.

References

Health Conditions

Health conditions that Methoxy-substituted benzoquinones may help support.

No conditions available.

Body Systems

Body systems that Methoxy-substituted benzoquinones may help support.

No body systems available.